LIFECORE BIOMEDICAL, INC. Operating Lease, Expense
LIFECORE BIOMEDICAL, INC. (LFCR) reported Operating Lease, Expense of $7.30 million for the 12-month period ending 2019-05-26, per its 10-K filed 2020-08-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2020-08-14
- LIFECORE BIOMEDICAL, INC. operating lease, expense for fiscal 2019 was $7.30M, a 19.67% increase from fiscal 2018.
- LIFECORE BIOMEDICAL, INC. operating lease, expense for fiscal 2018 was $6.10M.
| Period end | Operating Lease, Expense 12 month |
|---|---|
| 2019-05-26 | $7.30M 10-K · filed 2020-08-14 |
| 2018-05-27 | $6.10M 10-K · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |